MADRIGAL PHARMACEUTICALS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+210.8% +$218M
$321M
Cost of Revenue
$5M
R&D↑+353.3% +$91M
$116M
SG&A↑+69.9% +$99M
$240M
D&A↑+8.0% +$29K
$392K
Operating Income↑+2.0% +$2M
$-114M
EBITDA↑+8.0% +$29K
$392K
Interest Expense↑+137.1% +$5M
$8M
Interest Income↓-14.6% -$2M
$9M
Net Income↓-6.8% -$7M
$-114M
Operating Margin↑+147.4pts
-39.7%
Net Margin↑+132.3pts
-39.8%
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
Operating Lease Cost↑+158.0% +$1M
$2M
Revenue YoY Variation
210.8%
Income YoY Variation↑+20.0pts
2.0%
Revenue QoQ Variation↓-54.4pts
11.8%
Income QoQ Variation↓-169.9pts
-141.5%